Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma.
Fauvre A, Machu M, Merienne A, Vie N, Bessede T, Robin M, Garambois V, Taffoni C, Laguette N, Gervois-Segain N, Jarry A, Labarriere N, Allory Y, Larbouret C, Gros L, Tosi D, Solit DB, Pourquier P, Houédé N, Gongora C. Fauvre A, et al. Among authors: garambois v. Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011. Clin Transl Med. 2024. PMID: 39269751 Free PMC article. No abstract available.
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E, Garambois V, Hubert J, Bruciamacchie M, Pirot N, Delpech H, Broyon M, Theillet C, Colombo PE, Vie N, Tosi D, Gongora C, Khellaf L, Jarlier M, Radosevic-Robin N, Chardès T, Pèlegrin A, Larbouret C. Rabia E, et al. Among authors: garambois v. MAbs. 2021 Jan-Dec;13(1):1914883. doi: 10.1080/19420862.2021.1914883. MAbs. 2021. PMID: 33876707 Free PMC article.
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C, Colombo PE, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C. Ogier C, et al. Among authors: garambois v. Cancer Lett. 2018 Sep 28;432:227-236. doi: 10.1016/j.canlet.2018.06.023. Epub 2018 Jun 20. Cancer Lett. 2018. PMID: 29935372
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.
Combès E, Andrade AF, Tosi D, Michaud HA, Coquel F, Garambois V, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Moreaux J, Martineau P, Del Rio M, Beijersbergen RL, Vezzio-Vie N, Gongora C. Combès E, et al. Among authors: garambois v. Cancer Res. 2019 Jun 1;79(11):2933-2946. doi: 10.1158/0008-5472.CAN-18-2807. Epub 2019 Apr 15. Cancer Res. 2019. PMID: 30987998
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.
Cherradi S, Garambois V, Marines J, Andrade AF, Fauvre A, Morand O, Fargal M, Mancouri F, Ayrolles-Torro A, Vezzo-Vié N, Jarlier M, Loussaint G, Huvelle S, Joubert N, Mazard T, Gongora C, Pourquier P, Boissière-Michot F, Rio MD. Cherradi S, et al. Among authors: garambois v. Cell Biosci. 2023 Apr 11;13(1):72. doi: 10.1186/s13578-023-01015-5. Cell Biosci. 2023. PMID: 37041570 Free PMC article.
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Rabia E, Garambois V, Dhommée C, Larbouret C, Lajoie L, Buscail Y, Jimenez-Dominguez G, Choblet-Thery S, Liaudet-Coopman E, Cerutti M, Jarlier M, Ravel P, Gros L, Pirot N, Thibault G, Zhukovsky EA, Gérard PE, Pèlegrin A, Colinge J, Chardès T. Rabia E, et al. Among authors: garambois v. Front Immunol. 2023 Apr 20;14:1168444. doi: 10.3389/fimmu.2023.1168444. eCollection 2023. Front Immunol. 2023. PMID: 37153618 Free PMC article.
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Lazrek Y, et al. Among authors: garambois v. Neoplasia. 2013 Mar;15(3):335-47. doi: 10.1593/neo.121960. Neoplasia. 2013. PMID: 23479511 Free PMC article.
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud HA, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C. Bourillon L, et al. Among authors: garambois v. Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1039-1051. doi: 10.1016/j.ijrobp.2019.12.020. Epub 2020 Jan 17. Int J Radiat Oncol Biol Phys. 2020. PMID: 31959545
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking.
Lanotte R, Garambois V, Gaborit N, Larbouret C, Musnier A, Martineau P, Pèlegrin A, Chardès T. Lanotte R, et al. Among authors: garambois v. Cancer Sci. 2020 Jul;111(7):2508-2525. doi: 10.1111/cas.14458. Epub 2020 Jun 8. Cancer Sci. 2020. PMID: 32415868 Free PMC article.
34 results